Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.
The Times Mirror Company; Los Angeles Times - January 24, 1994, Monday, Home Edition PAGE: A-20
Art Pine; Times Staff Writer
Officials said the decision was announced in a Jan. 4 letter from Edward D. Martin, acting assistant secretary of defense for health policy, to the National Institutes of Health and the Food and Drug Administration. Both agencies had opposed continuing the trials.
Martin's letter said the Defense Department would instead turn the $20 million over to the Army to conduct more broadly based research on acquired immune deficiency syndrome.
He did not specify what the new research would entail, and officials said no firm decision had been made.
The program had been controversial almost from the start. Although the NIH and FDA both had recommended against conducting the trials so soon, MicroGeneSys, the Connecticut-based manufacturer of the vaccine, successfully lobbied Congress to mandate the tests.
The vaccine, known as VaxSyn, is designed only to slow the progress of AIDS, not to prevent infection with the human immunodeficiency virus that causes the disease.
The drug contains gp-160, which is made from fragments of the outer membrane of HIV in order to help attune patients' immune systems to the virus.
Some researchers and AIDS activists had complained of political meddling in connection with the tests. Although the Defense Department has frequently conducted trials of drugs, the selection traditionally has been made by the NIH rather than Congress.
Martin's letter was part of a package that also included recommendations by FDA Commissioner David A. Kessler and NIH Director Harold E. Varmus that the government not continue the trials involving a single drug.
An amendment to this past year's defense appropriation bill would have required the Pentagon to go ahead with the third phase of the trials unless the Defense Department, the NIH and the FDA all recommended against further testing.
940124
LT940108
Copyright © 1994 - Los Angeles Times. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Los Angeles Times, Permissions, Times Mirror Square, Los Angeles, CA 90053. http://www.latimes.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .